Drug Trial News

RSS

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Tizanidine looked promising early in a migraine trial, but the benefit did not last

A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in headache burden over 12 weeks in people with episodic migraine, despite a transient improvement with the 1 mg dose at week 4. Exploratory analyses suggested that smoking and sex may influence tizanidine exposure, while sex-specific efficacy signals remained hypothesis-generating and require confirmation.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

High-dose flu vaccine protects older adults with lung disease

The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

8 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Oral drug offers promising advance for children with achondroplasia

A phase 3 trial is showing "a potentially giant step forward," in treating children with achondroplasia, UCLA Health's Dr. Isidro B. Salusky wrote in a new editorial published in the New England Journal of Medicine (NEJM).

4 Sep 2026

Prednisone may impair bone health in children with Duchenne muscular dystrophy

In a new study published in Scientific Reports, an international and multidisciplinary research team including Binghamton University researchers identified a set of blood proteins that may explain why the corticosteroid prednisone, although beneficial in treating Duchenne muscular dystrophy (DMD), can interfere with childhood growth and bone health.

4 Sep 2026

More major insurance companies covering Kerecis intact fish-skin grafts as new studies show big benefits for burns and diabetic foot ulcers

Kerecis, the company pioneering the use of sustainably sourced fish‑skin grafts in cellular therapy and tissue regeneration, has significantly expanded U.S. insurance coverage, adding more than 40 million covered lives through recent policy updates across multiple large national and regional insurers, as well as state Medicaid programs.

3 Sep 2026

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Antiviral COVID-19 drug shows no benefit for Long COVID

Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.

1 Sep 2026

Laser-based therapy shows promise against dangerous abdominal infections in children

Children whose appendix has burst often develop serious abdominal infections that are hard to treat and increasingly resistant to antibiotics.

1 Sep 2026

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumors may influence how effectively a promising new generation of medicines can remove them, a study suggests.

31 Aug 2026

SHASTA trials show substantial triglyceride reductions with plozasiran

Plozasiran significantly reduced triglyceride levels in severe hypertriglyceridemia patients, showing promise in preventing acute pancreatitis after one year.

31 Aug 2026

Oral relaxin agonist AZD5462 improves cardiac function in heart failure patients

The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026

H-ISDN shows no significant benefit in broader heart failure population

In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.

30 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026